Tablets & Capsules

TC0419

Issue link: https://www.e-digitaleditions.com/i/1101841

Contents of this Issue

Navigation

Page 23 of 55

22 April 2019 Tablets & Capsules tion apparatus, as shown in Figure 10. The data shown in Figure 11 were obtained using this apparatus (at 37˚C, using a stirring rate of 100 rpm), employing 20 milliliters of artificial saliva. These data show that API release under these conditions can be restricted to varying degrees, depending on the amount of coating applied. For example, there was essentially no API Figure 10 µDiss Profiler dissolution apparatus Figure 11 Dissolution data for uncoated and coated mini-tablets using a µDiss Profiler dissolution apparatus 12.000 10.000 8.000 6.000 4.000 2.000 0.000 0 50 100 150 200 250 300 350 Drug release (percent) Uncoated Prime BAP 20% Protect BWT 20% Protect BWA 20% Protect BWA 30% Time (seconds) To achieve the joint objective of effective taste masking and subsequent rapid API release once the dosage form is swallowed, the API release must be lim- ited while the dosage form remains on the tongue. One way of assessing this requirement is to measure dissolution behavior in a limited amount of artificial saliva. This can be done using a µDiss Profiler dissolu-

Articles in this issue

Links on this page

Archives of this issue

view archives of Tablets & Capsules - TC0419